Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Payables (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Payables for 4 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • Quarterly Payables fell 2.11% to $4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Dec 2025, down 2.11% year-over-year, with the annual reading at $4.2 million for FY2025, 2.11% down from the prior year.
  • Payables for Q4 2025 was $4.2 million at LENZ Therapeutics, down from $4.3 million in the prior quarter.
  • The five-year high for Payables was $7.1 million in Q1 2024, with the low at $2.0 million in Q1 2023.
  • Average Payables over 4 years is $3.7 million, with a median of $3.7 million recorded in 2025.
  • The sharpest move saw Payables surged 257.98% in 2024, then tumbled 48.66% in 2025.
  • Over 4 years, Payables stood at $2.6 million in 2022, then surged by 43.9% to $3.8 million in 2023, then increased by 13.43% to $4.3 million in 2024, then fell by 2.11% to $4.2 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $4.2 million, $4.3 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.